Role of genetic testing in inherited cardiovascular disease: A review

JAMA Cardiology

Volumn 2, Issue 10, 2017, Pages 1153-1160

  Cirino, Allison L ^a   Harris, Stephanie ^a   Lakdawala, Neal K ^a   Michels, Michelle ^b   Olivotto, Iacopo ^c   Day, Sharlene M ^d   Abrams, Dominic J ^e   Charron, Philippe ^f   Caleshu, Colleen ^g   Semsarian, Christopher ^h   Ingles, Jodie ^h   Rakowski, Harry ⁱ   Judge, Daniel P ^j   Ho, Carolyn Y ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE;

CARDIOVASCULAR DISEASE; CLINICAL OUTCOME; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE MARKER; ENZYME REPLACEMENT; FABRY DISEASE; FAMILY COUNSELING; FAMILY HISTORY; FAMILY STUDY; GENE SEQUENCE; GENETIC DISORDER; GENETIC HETEROGENEITY; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; HUMAN GENOME; INHERITANCE; INTERPERSONAL COMMUNICATION; LABORATORY TEST; LOEYS DIETZ SYNDROME; MARFAN SYNDROME; MEDICAL EXPERT; MOLECULAR DIAGNOSIS; PATIENT CARE; PENETRANCE; PERSONALIZED MEDICINE; PHENOTYPE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVIEW; WHOLE EXOME SEQUENCING; GENETICS; HUMAN RELATION; PATIENT SELECTION; PEDIGREE; RISK FACTOR;

CARDIOVASCULAR DISEASES; COMMUNICATION; GENETIC TESTING; GENOME, HUMAN; HUMANS; PATIENT SELECTION; PEDIGREE; PROFESSIONAL-FAMILY RELATIONS; RISK FACTORS; WHOLE EXOME SEQUENCING;

EID: 85032499322     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2017.2352     Document Type: Review

References (40)

1. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001;104(4):557-567.
2. McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet. 2000;355(9221):2119-2124.
3. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80(5):795-803.
4. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352 (6333):337-339.
5. Gersh BJ, Maron BJ, Bonow RO, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):e783-e831.
6. Ackerman MJ, Priori SG, Willems S, et al; Heart Rhythm Society (HRS); European Heart Rhythm Association (EHRA). HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA) [published correction appears in Europace. 2012;14(2):277]. Europace. 2011;13(8):1077-1109.
7. Elliott PM, Anastasakis A, Borger MA, et al; Authors/Task Force members. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779.
8. Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MR, Towbin JA; Heart Failure Society of America. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2009;15(2):83-97.
9. Hiratzka LF, Bakris GL, Beckman JA, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American College of Radiology; American Stroke Association; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society of Thoracic Surgeons; Society for Vascular Medicine. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine. J Am Coll Cardiol. 2010;55(14):e27-e129.
10. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932-1963.
11. Charron P, Arad M, Arbustini E, et al; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31(22):2715-2726.
12. Bonter K, Desjardins C, Currier N, Pun J, Ashbury FD. Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open. 2011;1 (1):e000110.
13. Mainous AG III, Johnson SP, Chirina S, Baker R. Academic family physicians’ perception of genetic testing and integration into practice: a CERA study. Fam Med. 2013;45(4):257-262.
14. Mital S, Musunuru K, Garg V, et al; American Heart Association Council on Functional Genomics and Translational Biology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Stroke Council; Council on Lifestyle and Cardiometabolic Health; Council on Quality of Care and Outcomes Research. Enhancing literacy in cardiovascular genetics: a scientific statement from the American Heart Association. Circ Cardiovasc Genet. 2016;9(5):448-467.
15. Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation. 2011;123(23): 2701-2709.
16. Probst V, Wilde AA, Barc J, et al. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovasc Genet. 2009;2(6):552-557.
17. Borry P, Evers-Kiebooms G, Cornel MC, Clarke A, Dierickx K; Public and Professional Policy Committee (PPPC) of the European Society of Human Genetics (ESHG). Genetic testing in asymptomatic minors: background considerations towards ESHG recommendations. Eur J Hum Genet. 2009;17(6):711-719.
18. Ingles J, Sarina T, Yeates L, et al. Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med. 2013;15 (12):972-977.
19. Gruner C, Ivanov J, Care M, et al. Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2013;6(1): 19-26.
20. Bai R, Napolitano C, Bloise R, Monteforte N, Priori SG. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol. 2009;2(1):6-15.
21. Ackerman JP, Bartos DC, Kapplinger JD, Tester DJ, Delisle BP, Ackerman MJ. The promise and peril of precision medicine: phenotyping still matters most. Mayo Clin Proc. 2016;S0025-6196(16)30463-3.
22. Waddell-Smith KE, Donoghue T, Oates S, et al. Inpatient detection of cardiac-inherited disease: the impact of improving family history taking [published online October 8, 2016]. Open Heart. doi:10.1016/j.mayocp.2016.08.008
23. Alfares AA, Kelly MA, McDermott G, et al. Results of clinical genetic testing of 2912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med. 2015;17(11):880-888.
24. Walsh R, Thomson KL, Ware JS, et al. Reassessment of mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2017;19(2):192-203.
25. Mogensen J, van Tintelen JP, Fokstuen S, et al. The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. Eur Heart J. 2015;36(22):1367-1370.
26. Ingles J, Semsarian C. Conveying a probabilistic genetic test result to families with an inherited heart disease. Heart Rhythm. 2014;11(6):1073-1078.
27. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
28. Auton A, Brooks LD, Durbin RM, et al; 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015;526 (7571):68-74.
29. National Heart, Lung, and Blood Institute. NHLBI Exome Sequencing Project (ESP): Exome Variant Server. http://evs.gs.washington.edu/EVS/. November 3, 2014. Accessed January 12, 2017.
30. Lek M, Karczewski KJ, Minikel EV, et al; Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285-291.
31. Das K J, Ingles J, Bagnall RD, Semsarian C. Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. Genet Med. 2014;16(4): 286-293.
32. Green RC, Lautenbach D, McGuire AL. GINA, genetic discrimination, and genomic medicine. N Engl J Med. 2015;372(5):397-399.
33. Clifton JM, VanBeuge SS, Mladenka C, Wosnik KK. The Genetic Information Nondiscrimination Act 2008: what clinicians should understand. J Am Acad Nurse Pract. 2010;22(5):246-249.
34. Caleshu C, Kasparian NA, Edwards KS, et al. Interdisciplinary psychosocial care for families with inherited cardiovascular diseases. Trends Cardiovasc Med. 2016;26(7):647-653.
35. Aatre RD, Day SM. Psychological issues in genetic testing for inherited cardiovascular diseases. Circ Cardiovasc Genet. 2011;4(1):81-90.
36. Burns C, McGaughran J, Davis A, Semsarian C, Ingles J. Factors influencing uptake of familial long QT syndrome genetic testing. Am J Med Genet A. 2016;170A(2):418-425.
37. Forrest LE, Delatycki MB, Skene L, Aitken M. Communicating genetic information in families - a review of guidelines and position papers. Eur J Hum Genet. 2007;15(6):612-618.
38. Green RC, Berg JS, Grody WW, et al; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565-574.
39. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19(2):249-255.
40. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med. 2014;371(12):1170.